These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30349995)

  • 21. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism.
    Dunne FP; Elliot P; Gammage MD; Stallard T; Ryan T; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):623-9. PubMed ID: 8548948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long term treatment with growth hormone deficiency in adults].
    Cabo D; Lecube A; Barrios M; Mesa J
    Med Clin (Barc); 2011 May; 136(15):659-64. PubMed ID: 21411111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement.
    Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3773-9. PubMed ID: 16849414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables.
    Abrams P; Boquete H; Fideleff H; Feldt-Rasmussen U; Jönsson PJ; Koltowska-Häggström M; Wilton P; Abs R
    Eur J Endocrinol; 2008 Dec; 159(6):825-32. PubMed ID: 18713841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption.
    Svensson J; Mattsson A; Rosén T; Wirén L; Johannsson G; Bengtsson BA; Koltowska Häggström M;
    Growth Horm IGF Res; 2004 Jun; 14(3):207-15. PubMed ID: 15125882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency.
    Mazziotti G; Porcelli T; Bianchi A; Cimino V; Patelli I; Mejia C; Fusco A; Giampietro A; De Marinis L; Giustina A
    Eur J Endocrinol; 2010 Jul; 163(1):15-20. PubMed ID: 20378720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).
    Rosilio M; Blum WF; Edwards DJ; Shavrikova EP; Valle D; Lamberts SW; Erfurth EM; Webb SM; Ross RJ; Chihara K; Henrich G; Herschbach P; Attanasio AF
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1684-93. PubMed ID: 15070931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients.
    Dullaart RP; Schols JL; van der Steege G; Zelissen PM; Sluiter WJ; van Beek AP
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):359-66. PubMed ID: 18221399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients.
    Toogood AA; Taylor NF; Shalet SM; Monson JP
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1727-30. PubMed ID: 10770221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism.
    Peacey SR; Wright D; Aye M; Moisey R
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):94-8. PubMed ID: 22151005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects on insulin action in adult hypopituitarism of recombinant human GH therapy individually titrated for six months.
    McConnell EM; Atkinson AB; Ennis C; Hadden DR; McCance DR; Sheridan B; Bell PM
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5342-7. PubMed ID: 11701703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients.
    Behan LA; Kelleher G; Hannon MJ; Brady JJ; Rogers B; Tormey W; Smith D; Thompson CJ; McKenna MJ; Agha A
    Eur J Endocrinol; 2014 Jan; 170(1):141-50. PubMed ID: 24123094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults.
    Holdaway IM; Hunt P; Manning P; Cutfield W; Gamble G; Ninow N; Staples-Moon D; Moodie P; Metcalfe S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):85-90. PubMed ID: 25523467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults?
    Chrisoulidou A; Kousta E; Beshyah SA; Robinson S; Johnston DG
    Baillieres Clin Endocrinol Metab; 1998 Jul; 12(2):261-79. PubMed ID: 10083896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.
    Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1542-9. PubMed ID: 15613427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy.
    Nishizawa H; Iguchi G; Murawaki A; Fukuoka H; Hayashi Y; Kaji H; Yamamoto M; Suda K; Takahashi M; Seo Y; Yano Y; Kitazawa R; Kitazawa S; Koga M; Okimura Y; Chihara K; Takahashi Y
    Eur J Endocrinol; 2012 Jul; 167(1):67-74. PubMed ID: 22535644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency.
    Kołtowska-Haggstrom M; Hennessy S; Mattsson AF; Monson JP; Kind P
    Horm Res; 2005; 64(1):46-54. PubMed ID: 16103683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.